Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

This study is testing different immunotherapy combinations — including drugs called APL-2, pembrolizumab, and bevacizumab — for women with high-grade serous ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based chemotherapy. **You may be eligible if:** - You are a woman 18 or older with platinum-resistant high-grade serous ovarian, fallopian tube, or peritoneal cancer - You have measurable disease on imaging - You have good overall health (ECOG status 0 or 1) - You are willing to undergo tumor biopsies before and during treatment - Your blood counts, kidney, and liver function are within acceptable ranges **You may NOT be eligible if:** - You have received more than one chemotherapy regimen for platinum-resistant disease - You have brain metastases with symptoms requiring steroids - You have active autoimmune disease requiring chronic steroids - You have had a recent heart attack, stroke, or significant heart disease in the last 6 months - You are pregnant or breastfeeding - You have active hepatitis B, hepatitis C, or HIV Talk to your doctor to see if this trial is right for you.